[go: up one dir, main page]

MA26698A1 - Composition pharmaceutique concentree liquide de sertraline et procede pour sa preparation - Google Patents

Composition pharmaceutique concentree liquide de sertraline et procede pour sa preparation

Info

Publication number
MA26698A1
MA26698A1 MA25814A MA25814A MA26698A1 MA 26698 A1 MA26698 A1 MA 26698A1 MA 25814 A MA25814 A MA 25814A MA 25814 A MA25814 A MA 25814A MA 26698 A1 MA26698 A1 MA 26698A1
Authority
MA
Morocco
Prior art keywords
sertraline
pharmaceutical composition
preparation
concentrated pharmaceutical
liquid concentrated
Prior art date
Application number
MA25814A
Other languages
English (en)
Inventor
Mckowan Welch Willard
Jane Harper Nancy
Ramchandra Ranade Gautam
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22298286&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA26698(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26698A1 publication Critical patent/MA26698A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

DEPOSANT Société dite : PFIZER PRODUCTS INC. REVENDICATION DE PRIORITES US 13/10/1998 60/104 024 Voir en annexe le titre de l'invention et le texte de l'abrégé "Composition pharmaceutique concentrée liquide de sertraline et procédé pour sa préparation" L'invention concerne une composition pharmaceutique concentrée liquide, pratiquement non aqueuse, pour l'administration orale, contenant de la sertraline et un excipient. Elle concerne également l'utilisation de cette composition concentrée pour préparer une solution aqueuse de sertraline. Application : utilisation de cette composition ou solution pour le traitement ou la prévention de diverses maladies.
MA25814A 1998-10-13 1999-10-12 Composition pharmaceutique concentree liquide de sertraline et procede pour sa preparation MA26698A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10402498P 1998-10-13 1998-10-13

Publications (1)

Publication Number Publication Date
MA26698A1 true MA26698A1 (fr) 2004-12-20

Family

ID=22298286

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25814A MA26698A1 (fr) 1998-10-13 1999-10-12 Composition pharmaceutique concentree liquide de sertraline et procede pour sa preparation

Country Status (45)

Country Link
EP (1) EP1121107B1 (fr)
JP (1) JP3792514B2 (fr)
KR (1) KR100417200B1 (fr)
CN (1) CN1184962C (fr)
AP (1) AP2001002119A0 (fr)
AR (1) AR014082A1 (fr)
AT (1) ATE254453T1 (fr)
AU (1) AU766202B2 (fr)
BG (1) BG65085B1 (fr)
BR (1) BR9914418A (fr)
CA (1) CA2346335C (fr)
CO (1) CO5150213A1 (fr)
CZ (1) CZ20011286A3 (fr)
DE (1) DE69912978T2 (fr)
DK (1) DK1121107T3 (fr)
DZ (1) DZ2913A1 (fr)
EA (1) EA003990B1 (fr)
EE (1) EE04868B1 (fr)
EG (1) EG23818A (fr)
ES (1) ES2209490T3 (fr)
GC (1) GC0000175A (fr)
GE (1) GEP20032969B (fr)
GT (1) GT199900171A (fr)
HK (1) HK1040199B (fr)
HR (1) HRP20010263B1 (fr)
HU (1) HUP0104470A3 (fr)
ID (1) ID29845A (fr)
IS (1) IS2239B (fr)
MA (1) MA26698A1 (fr)
MY (1) MY122477A (fr)
NO (1) NO20011829L (fr)
NZ (1) NZ510756A (fr)
OA (1) OA11662A (fr)
PA (1) PA8483301A1 (fr)
PE (1) PE20001108A1 (fr)
PL (1) PL348119A1 (fr)
PT (1) PT1121107E (fr)
SK (1) SK4582001A3 (fr)
TN (1) TNSN99190A1 (fr)
TR (1) TR200101090T2 (fr)
TW (1) TWI228043B (fr)
UA (1) UA72743C2 (fr)
WO (1) WO2000021521A2 (fr)
YU (1) YU26401A (fr)
ZA (1) ZA200102900B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60026146T2 (de) 1999-09-03 2006-08-17 Apbi Holdings, Llc Verwendung von Dapoxetin, A selektiver Serotonin Aufnahme Inhibitor mit schnellem Wirkungseintritt, zur Behandlung von sexueller Disfunktion
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
WO2004065348A1 (fr) 2003-01-23 2004-08-05 Pfizer Products Inc. Sels pharmaceutiquement acceptables de sertraline et compositions pharmaceutiques correspondantes
US7186863B2 (en) 2003-05-23 2007-03-06 Transform Pharmaceuticals, Inc. Sertraline compositions
WO2005034910A1 (fr) * 2003-10-08 2005-04-21 Ranbaxy Laboratories Limited Compositions pharmaceutiques liquides de sertraline a administration orale
WO2007052152A2 (fr) * 2005-11-07 2007-05-10 Aurobindo Pharma Limited Concentré oral d'un antidépresseur
US20080268067A1 (en) * 2007-03-09 2008-10-30 Llinas Rodolfo R Methods and Compositions for Treating Thalamocortical Dysrhythmia
CN109908354A (zh) * 2017-12-12 2019-06-21 万特制药(海南)有限公司 盐酸舍曲林口服浓缩液及其制备工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
EP0415612B1 (fr) * 1989-08-30 1993-11-10 Pfizer Inc. Utilisation de la sertraline pour le traitement des dépendances aux produits chimiques
US5130338A (en) * 1989-08-30 1992-07-14 Pfizer Inc. Method of treating chemical dependencies using sertraline
US4940731A (en) * 1989-08-30 1990-07-10 Pfizer Inc. Method of treating premature ejaculation using sertraline
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
CA2143070C (fr) * 1994-02-22 2001-12-18 Pankaj Modi Formulation pharmaceutique sous forme de suspension liquide administree par voie orale, pour degagement prolonge
US5597826A (en) * 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
SE508372C2 (sv) * 1995-02-13 1998-09-28 Kjell Lindstroem Metod och utrustning för tillförsel eller aspiration av substanser inom gastrointestinalkanalen, avsedd för mätning av farmakokinetiska och fysikalisk-kemiska parametrar
DE69626916T2 (de) * 1995-07-17 2003-10-09 Pfizer Inc., New York Sertralin zur Behandlung von Post-Myocard-Infarkt-Patienten
PT980241E (pt) * 1997-07-01 2004-03-31 Pfizer Prod Inc Formas de dosagem encapsuladas em gelatina de sertralina em solucao

Also Published As

Publication number Publication date
CA2346335C (fr) 2006-04-18
SK4582001A3 (en) 2002-02-05
EA200100285A1 (ru) 2001-10-22
IS2239B (is) 2007-05-15
KR20010080096A (ko) 2001-08-22
ATE254453T1 (de) 2003-12-15
AR014082A1 (es) 2001-01-31
MY122477A (en) 2006-04-29
EP1121107B1 (fr) 2003-11-19
NZ510756A (en) 2003-05-30
HK1040199A1 (en) 2002-05-31
DE69912978T2 (de) 2004-04-22
CN1184962C (zh) 2005-01-19
PT1121107E (pt) 2004-02-27
PA8483301A1 (es) 2000-09-29
GC0000175A (en) 2006-03-29
AU766202B2 (en) 2003-10-09
TWI228043B (en) 2005-02-21
CA2346335A1 (fr) 2000-04-20
CO5150213A1 (es) 2002-04-29
PL348119A1 (en) 2002-05-06
WO2000021521A2 (fr) 2000-04-20
JP3792514B2 (ja) 2006-07-05
NO20011829L (no) 2001-06-05
TR200101090T2 (tr) 2001-12-21
ID29845A (id) 2001-10-18
KR100417200B1 (ko) 2004-02-05
OA11662A (en) 2004-12-08
TNSN99190A1 (fr) 2005-11-10
EG23818A (en) 2007-09-19
DE69912978D1 (de) 2003-12-24
DK1121107T3 (da) 2004-02-23
WO2000021521A3 (fr) 2000-07-20
ZA200102900B (en) 2002-05-29
HRP20010263A2 (en) 2002-06-30
YU26401A (sh) 2005-07-19
EE04868B1 (et) 2007-08-15
HK1040199B (zh) 2005-05-27
BG65085B1 (bg) 2007-02-28
CZ20011286A3 (cs) 2001-09-12
DZ2913A1 (fr) 2004-03-01
ES2209490T3 (es) 2004-06-16
EP1121107A2 (fr) 2001-08-08
EE200100221A (et) 2002-08-15
AU5643699A (en) 2000-05-01
CN1323202A (zh) 2001-11-21
NO20011829D0 (no) 2001-04-10
PE20001108A1 (es) 2000-10-26
AP2001002119A0 (en) 2001-03-22
BR9914418A (pt) 2001-06-26
GT199900171A (es) 2001-03-28
IS5906A (is) 2001-03-23
HUP0104470A3 (en) 2003-12-29
JP2002527385A (ja) 2002-08-27
BG105434A (en) 2001-12-29
HUP0104470A2 (en) 2002-08-28
HRP20010263B1 (en) 2005-04-30
EA003990B1 (ru) 2003-12-25
UA72743C2 (en) 2005-04-15
GEP20032969B (en) 2003-05-27

Similar Documents

Publication Publication Date Title
MA26723A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26700A1 (fr) FORMULATIONS PHARMACEUTIQUES D'INHIBITEURS DE PDE-5 DE GMPc à LIBERATION CONTROLEE, ET PROCEDE POUR LEUR PREPARATION.
MA26688A1 (fr) 4-carboxamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
JO3404B1 (ar) تركيبة صيدلانية سائلة تحتوي على مشتقات اريثروبويتين
DE69940769D1 (de) Orale flüssige zusammensetzungen
CA2185036A1 (fr) Utilisation d'un extrait d'une bacterie filamenteuse non photosynthetique et composition le contenant
MA26689A1 (fr) Derives de tetrahydroquinoleine substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
EP0765160A4 (fr)
EE03253B1 (et) (R)-5-karbamoüül-8-fluoro-3-N,N-diasendatud-amino-3,4-dihüdro-2H-1-bensopüraani d, nende valmistamise protsess ja neid sisaldavad ravimkoostised
TNSN00252A1 (fr) Compositions pharmaceutiques engendrant des concentrations accrues de medicaments
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
BR9908488A (pt) Composição farmacêutica de topiramato
MA27093A1 (fr) Derives de sulfonamides, leur preparation et leur application comme medicaments.
MA26701A1 (fr) PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSTIONS PHARMACEUTIQUES LES CONTENANT.
MA26690A1 (fr) COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE PYRIDO [1,2-a ] PYRAZINE ET PROCEDE POUR LEUR PREPARATION
MA27017A1 (fr) Procede pour la production d'une composition pharmaceutique a faible dose ayant une distribution et activite medicamenteuses uniformes
BE900564A (fr) Composition pharmaceutique pour le traitement d'arteriopathies peripheriques.
MA26698A1 (fr) Composition pharmaceutique concentree liquide de sertraline et procede pour sa preparation
MX9403088A (es) Composiciones farmaceuticas que contienen deriva- dos de indol y metodos de uso.
TNSN97143A1 (fr) Derives de trans-piperazine-1-yl-spiro(cyclohexane-1, 1'- isobenzofuranne), procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN87006A1 (fr) Derives de la benzazecine
BR9809519A (pt) Sal, processo para fabricação e uso do mesmo, formulação farmacêutica, e, processo para prevenção ou tratamento de distúrbios cns e perturbações médicas relacionadas
MA26726A1 (fr) Composition pharmaceutique de resorcinol, et procede pour sa preparation
IL102032A0 (en) 2-amino-5-cyano-1,4-dihydropyridines,their preparation and pharmaceutical compositions containing them
MA26734A1 (fr) Derives de 1-trifluoromethyl -4-hydroxy- 7-piperidinyl- aminomethylchromane, procede pour leur preparation et compositions pharmaceutiques les contenant